Samsung Electronics Co., Ltd.

Korea Institute of Science and Technology

Cj Cheiljedang Corporation

Neurobiogen Co., Ltd.

Megabiowood Co., Ltd

Yun Kyung Kim

Kang Kook Lee

Yul Joong Kim

Ji Yeon Kwak

Yong Yeon Lee

Hyun Jin Kim

Ae Nim Pae

Sung Su Lim

Dong Jin Kim

Hyun Ah Choo

Kyung Bae Park

Jong-Hyun Park

Kyung Ho Lee

Jin Ho Seo

Kyu Sik Kim

Jun Young Heo

Ji Won Choi

Sang Chul Sul

ChangJoon Justin Lee

Ki Duk Park

Yong Koo Kang

Seul Ki Yeon

Do Hee Kim

Tae Hun Kim

Kwang Hee Lee

Dong Goo Kang

Hoon Ryu

Ji Yeon Song

Hirosige Goto

Kyo Jin Choo

Sun Joon Min

Yong Seo Cho

Hyunah Choo

Kwang-hee Lee

Ji Yoon Kang

Eui Sung Yoon

Hyewhon Rhim

Soo Hyun Lee

Hyojin Kim

Gyo Chang Keum

Jae Kyun Lee

Ghil Soo Nam

Yeo Jun Yoon

Eun Kyoung Bang

Jae Wook Lee

Seul Gi Shin

Eun Ji Ju

Seon Mi Jo

Bo Ko Jang

Jei Won Cho

Il Joo Cho

Hyewon Seo

Younghee Kim

Hae Yoon Park

Jihye Seong

Hyo Jung Song

Min Ho Nam

Sang Min Lim

Sun-Joon Min

Yu Jin Hwang

Myoung Gun Jeon

Ahmed A Elbatrawy

Hyemyung Seo

Juhyeon Kim

Jong-hyun Park

Jihoon Jang

Sungsu Lim

Ha Eun Lee

Yi Jae Lee

Jin Ah Kong

Md Mamunul Haque

Eunji Cha

Kunhee Kim

Jee Yun Ahn

Ji Woong Lim

Nam Gyung Kim

Hye Yeon Lee

Ashwini Machhindra Londhe

Lizaveta Gotina

Chae Won Kim

Da Mi Lim

Seok Kyu Kim

Woo Seung Son

Haeun Lee

Hyean Jeong Jeong

Seulgi Shin

Disclosed are a compound with near-infrared fluorescence that selectively binds to tau aggregates, a method for preparing the same, a tau-targeting near-infrared fluorescent probe including the compound, a composition for detecting a tau fiber protein containing the near-infrared fluorescent probe as an active ingredient, and the use of the composition for the diagnosis of tauopathy. In particular, the compound does not bind to an amyloid beta protein and has high selectivity to a tau aggregate, specifically reported as an etiology of the initial state of tauopathy, thus being useful as a near-infrared fluorescent detector for detecting a tau fiber protein for early diagnosis of a tauopathy including Alzheimer's disease.

Compounds useful as near-infrared fluorescent probes selectively binding to tau aggregates and method of preparing the same

The present disclosure relates to a system for monitoring post-translational modification of protein using a biosensor with a gap, which performs with high reliability a diagnosis of a disease associated with a target protein for which impedance is measured, by measuring an impedance of a sample introduced into a sensor and calculating a change rate of the measured impedance, and to a method of manufacturing the biosensor used for the system.

System for monitoring post-translational modification of protein using bio-sensor with gap and manufacturing method for bio-sensor

The present disclosure relates to a vector pair for screening TDP-43 (TAR DNA-binding protein 43 or TransActive Response DNA-binding protein 43) oligomer formation, a cell line transfected with the vector pair, and a method of monitoring TDP-43 oligomer formation using the cell line. More specifically, the vector pair includes: a first vector including a first TDP-43 gene and a first fluorescence protein gene; and a second vector including a second TDP-43 gene and a second fluorescence protein gene, wherein a protein expressed from the first fluorescence protein gene and a protein expressed from the second fluorescence protein gene bind to each other to display fluorescence, by association between a protein expressed from the first TDP-43 gene and a protein expressed from the second TDP-43 gene. The vector pair is effective in that it makes it possible to monitor TDP-43 oligomer formation in living cells.

Pair of amino acid sequences for monitoring formation of TDP-43 oligomer in living cells via bimolecular fluorescence complementation

The present disclosure relates to an &#x3b1;-aminoamide derivative compound and a pharmaceutical composition containing the same. According to various embodiments of the present disclosure, provided is a therapeutic agent which can overcome the disadvantages of existing drugs used as a MAO-B inhibitor and, specifically, reversibly inhibits MAO-B through a non-covalent bond so as to alleviate or eliminate the side effects of the existing drugs which exhibit a therapeutic effect by irreversibly acting via a covalent bond with MAO-B. Particularly, a new compound having superior stability and efficacy compared to the existing reversible MAO-B inhibitors may be provided.

Alpha-aminoamide derivative compound and pharmaceutical composition comprising same

An electronic device includes a display including a transparent area through which content is output and through which external light passes and a processor electrically connected to the display. The processor is configured to obtain information about an overlap location of an external device and the electronic device, to execute a function mapped to the information about the overlap location, and to output a screen associated with the function on the transparent area.

Electronic device, and method for providing screen according to location of electronic device

The present disclosure relates to an &#x3b1;-aminoamide derivative compound and a pharmaceutical composition containing the same, for treating a neurodegenerative diseases.

Disclosed is a vector pair for screening tau oligomer formation, a mouse embryo introduced with the vector pair, a transgenic model mouse of neurological disease, obtained from the mouse embryo, and a method of screening a tau oligomer formation inhibitor candidate using the transgenic model mouse. More specifically, the present invention provides vector pair for screening tau oligomer formation, comprising: a first vector comprising a first tau gene, a first fluorescence protein gene and a first neuron-specific promoter; and a second vector comprising a second tau gene, a second fluorescence protein gene and a second neuron-specific promoter, wherein a protein expressed from the first fluorescence protein gene and a protein expressed from the second fluorescence protein gene bind to each other to display fluorescence, by association between a protein expressed from the first tau gene and a protein expressed from the second tau gene.

Transgenic mouse model for dementia

Bag for food packing

The present disclosure relates to a quinoline derivative which inhibits the activity of histone methyltransferases (ESET/SETDB1) specific for the histone molecule H3K9 or a pharmaceutically acceptable salt thereof and a use thereof.

Quinoline derivatives for inhibiting histone methyltransferases and use thereof

Disclosed is a levosimendan compound, an optically active isomer thereof, or a pharmaceutically acceptable salt thereof, which is used for the prevention and/or treatment of diseases caused by tau aggregation or phosphorylation, such as neurodegenerative diseases (e.g., Alzheimer disease). In accordance with yet another aspect of the present invention, there is provided a health functional food for preventing or treating tau aggregation-related diseases, containing a levosimendan compound or a pharmaceutically acceptable salt, stereoisomer or solvate thereof.

Levosimendan compound for preventing or treating tau-related diseases

Growing community of inventors

Seoul, South Korea

Yun Kyung Kim